Genetic Testing for Breast Cancer: Who Needs It and Why?

23 December 2025

Genetic testing plays an increasingly important role in breast cancer care. While most breast cancers occur sporadically, about 5–10% are hereditary, caused by inherited gene mutations that significantly increase cancer risk. Understanding who needs genetic testing can help with early detection, prevention, and treatment planning.

Genetic testing looks for mutations in specific genes most commonly BRCA1 and BRCA2 that increase the risk of breast and ovarian cancers. Other genes may also be tested depending on personal and family history. A positive result does not mean a person currently has cancer, but it does indicate a higher lifetime risk and the need for closer monitoring or preventive strategies.

Not every patient with breast cancer requires genetic testing. It is usually recommended for women diagnosed at a young age (typically below 45–50 years), those with triple-negative breast cancer, patients with bilateral or multiple cancers, or individuals with a strong family history of breast, ovarian, pancreatic, or prostate cancer. Men diagnosed with breast cancer and patients from families with known genetic mutations should also be considered for testing.

Genetic testing is not only about assessing risk it can also influence treatment decisions. Certain targeted therapies are more effective in patients with specific genetic mutations. In addition, test results can guide decisions about preventive surgery, enhanced screening, and risk reduction for family members.

Equally important is genetic counselling, both before and after testing. Counselling helps patients understand the implications of results, avoid unnecessary anxiety, and make informed medical decisions.

Genetic testing is provided with comprehensive counselling, helping patients understand their risks, testing options, and individualized care.

Understanding genetic risk empowers patients and families to take proactive steps turning information into prevention and personalized treatment.

In breast cancer care, the right knowledge can shape the right decisions.

- Medically reviewed by Dr. Kritika Mehrotra (Consultant, Medical Oncology)

Facebook
Twitter
LinkedIn
Email
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male